Video wird geladen...

Video konnte nicht geladen werden

Beim Laden dieses Videos ist ein Problem aufgetreten. Dies könnte an einem vorübergehenden Netzwerkproblem liegen oder das Video ist möglicherweise nicht verfügbar.

Statins Slash GLP-1: (~10-minute Data Digest for X) Human trial data published in a major journal show that statins cause insulin resistance and deplete GLP-1 levels in humans. This should have been breaking news... But no one talked about it. Why don’t doctors know? Why aren’t patients being informed... show more

Nick Norwitz MD PhD

124,597 subscribers

168,567 Aufrufe • vor 11 Monaten •via X (Twitter)

Gesundheit & Wellness Wissenschaft & Technologie

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Think your blood glucose tells the whole story? Think again. Dr. Ben Bikman (Benjamin Bikman) joins me to discuss insulin resistance, including why it often remains hidden until late stages and simple ways to detect it early. We explore insulin’s lesser-known roles in fat storage, appetite regulation, inflammation, and chronic disease. You’ll also learn how macronutrients, meal timing, and frequency uniquely influence your insulin sensitivity, and the critical differences between visceral and subcutaneous fat. Finally, we dive into how stress, sleep deprivation, nicotine, and environmental toxins shape your metabolism and unpack the realities of popular GLP-1 receptor agonist medications (like Ozempic), including their benefits, risks, and the intriguing potential of microdosing. We also provide practical, actionable strategies, dietary adjustments, exercise protocols, and targeted supplements that you can implement today to significantly boost insulin sensitivity and support long-term metabolic health. If you want to understand insulin resistance and take immediate steps to improve your metabolic health - this conversation is a must-watch. Watch the full episode on X and YouTube or listen on Spotify and Apple Podcasts now. Links in the comments. Timestamps: 0:00 - Introduction 1:33 - Can you be insulin resistant with normal glucose levels? 5:13 - Can glucose monitors detect hidden insulin resistance? 6:43 - What your skin reveals about insulin resistance 8:07 - Why is insulin resistance behind so many chronic diseases? 12:28 - Does obesity cause insulin resistance—or vice versa? 19:20 - Insulin’s surprising roles beyond blood sugar control 20:18 - What’s driving weight gain—insulin or calories? 27:12 - Do saturated fats cause insulin resistance? 33:44 - Why refined carbs amplify risks from saturated fat 36:46 - Fructose vs. refined sugar—which spikes insulin more? 37:43 - High-carb vs. keto—which diet controls hunger better? 42:09 - Why low-carb diets might provide a metabolic advantage 44:18 - Does exercise give you metabolic ‘wiggle room’? 48:42 - Why strength training beats cardio for insulin sensitivity 53:54 - Does meal frequency drive insulin resistance? 57:14 - Is nighttime snacking giving you insomnia? 59:06 - Can a sugary breakfast lead to overeating later? 1:04:01 - Does late-night eating disrupt sleep more than blue light? 1:05:41 - Can one bad night’s sleep trigger insulin resistance? 1:09:06 - Can air pollution cause weight gain? 1:12:58 - Vaping vs. smoking—which is worse for metabolic health? 1:14:20 - Can statins and antidepressants trigger weight gain? 1:17:04 - How to reverse insulin resistance in 90 days 1:27:35 - Ketone supplements—are the metabolic benefits real? 1:33:16 - Why some ethnicities get diabetes without obesity 1:41:11 - How oversized fat cells trigger metabolic chaos 1:46:10 - Do seed oils silently promote insulin resistance? 1:49:27 - Seed oils—always harmful or only when heated? 2:01:03 - Do fat cells shrink or disappear with weight loss? 2:03:48 - Are shrunken fat cells still insulin resistant? 2:06:23 - Injecting insulin for muscle—are the risks worth it? 2:09:27 - Are drugs like Ozempic a shortcut or solution for obesity? 2:15:55 - Are current GLP-1 agonist doses too high? 2:16:44 - Microdosing GLP-1 drugs—a solution for carb cravings? 2:22:43 - Do these medications cause muscle loss? 2:25:12 - Do GLP-1 agonist benefits extend beyond weight loss? 2:27:23 - Could these treatments actually promote longevity? 2:32:55 - The dark side of GLP-1 drugs—can they trigger depression? 2:36:14 - Insulin vs. glucose—what really drives accelerated aging? 2:41:16 - How high glucose levels damage cells 2:43:23 - How insulin shuts down your body’s stress defenses 2:47:57 - Which biomarkers best predict biological aging? 2:54:01 - Does eating dinner early improve insulin sensitivity?

Think your blood glucose tells the whole story? Think again. Dr. Ben Bikman (Benjamin Bikman) joins me to discuss insulin resistance, including why it often remains hidden until late stages and simple ways to detect it early. We explore insulin’s lesser-known roles in fat storage, appetite regulation, inflammation, and chronic disease. You’ll also learn how macronutrients, meal timing, and frequency uniquely influence your insulin sensitivity, and the critical differences between visceral and subcutaneous fat. Finally, we dive into how stress, sleep deprivation, nicotine, and environmental toxins shape your metabolism and unpack the realities of popular GLP-1 receptor agonist medications (like Ozempic), including their benefits, risks, and the intriguing potential of microdosing. We also provide practical, actionable strategies, dietary adjustments, exercise protocols, and targeted supplements that you can implement today to significantly boost insulin sensitivity and support long-term metabolic health. If you want to understand insulin resistance and take immediate steps to improve your metabolic health - this conversation is a must-watch. Watch the full episode on X and YouTube or listen on Spotify and Apple Podcasts now. Links in the comments. Timestamps: 0:00 - Introduction 1:33 - Can you be insulin resistant with normal glucose levels? 5:13 - Can glucose monitors detect hidden insulin resistance? 6:43 - What your skin reveals about insulin resistance 8:07 - Why is insulin resistance behind so many chronic diseases? 12:28 - Does obesity cause insulin resistance—or vice versa? 19:20 - Insulin’s surprising roles beyond blood sugar control 20:18 - What’s driving weight gain—insulin or calories? 27:12 - Do saturated fats cause insulin resistance? 33:44 - Why refined carbs amplify risks from saturated fat 36:46 - Fructose vs. refined sugar—which spikes insulin more? 37:43 - High-carb vs. keto—which diet controls hunger better? 42:09 - Why low-carb diets might provide a metabolic advantage 44:18 - Does exercise give you metabolic ‘wiggle room’? 48:42 - Why strength training beats cardio for insulin sensitivity 53:54 - Does meal frequency drive insulin resistance? 57:14 - Is nighttime snacking giving you insomnia? 59:06 - Can a sugary breakfast lead to overeating later? 1:04:01 - Does late-night eating disrupt sleep more than blue light? 1:05:41 - Can one bad night’s sleep trigger insulin resistance? 1:09:06 - Can air pollution cause weight gain? 1:12:58 - Vaping vs. smoking—which is worse for metabolic health? 1:14:20 - Can statins and antidepressants trigger weight gain? 1:17:04 - How to reverse insulin resistance in 90 days 1:27:35 - Ketone supplements—are the metabolic benefits real? 1:33:16 - Why some ethnicities get diabetes without obesity 1:41:11 - How oversized fat cells trigger metabolic chaos 1:46:10 - Do seed oils silently promote insulin resistance? 1:49:27 - Seed oils—always harmful or only when heated? 2:01:03 - Do fat cells shrink or disappear with weight loss? 2:03:48 - Are shrunken fat cells still insulin resistant? 2:06:23 - Injecting insulin for muscle—are the risks worth it? 2:09:27 - Are drugs like Ozempic a shortcut or solution for obesity? 2:15:55 - Are current GLP-1 agonist doses too high? 2:16:44 - Microdosing GLP-1 drugs—a solution for carb cravings? 2:22:43 - Do these medications cause muscle loss? 2:25:12 - Do GLP-1 agonist benefits extend beyond weight loss? 2:27:23 - Could these treatments actually promote longevity? 2:32:55 - The dark side of GLP-1 drugs—can they trigger depression? 2:36:14 - Insulin vs. glucose—what really drives accelerated aging? 2:41:16 - How high glucose levels damage cells 2:43:23 - How insulin shuts down your body’s stress defenses 2:47:57 - Which biomarkers best predict biological aging? 2:54:01 - Does eating dinner early improve insulin sensitivity?

Dr. Rhonda Patrick

148,954 Aufrufe • vor 1 Jahr

New episode of HARD DRUGS! Should everyone be taking statins? Statins have revolutionised heart disease and they're one of many reasons for the long-term decline in cardiovascular mortality. Clinical trials suggest that the more you reduce LDL cholesterol levels, the more you reduce the risks of heart attacks and strokes, with no signal of harms even at the lowest levels. So scientists recommend the earlier they're taken the better, and the lower LDL levels you reach the better. Statins do have some rare side effects – such as muscle weakness and muscle loss in rare cases – but meta-analyses of RCTs find that most other side effects listed on statins' labels do not actually have higher risks than placebo. In this episode, Jacob Trefethen and I chat about all this and much more! - Why it took almost a century for scientists to come to consensus on "the lipid hypothesis": that higher levels of plasma LDL cholesterol causes higher risks of heart disease and that reducing it saves lives. - Drugs that effectively reduce cholesterol levels beyond the effect of statins, such as PCSK9 inhibitors, most of which are monoclonal antibodies, as well as newer siRNA drugs and the macrocyclic peptide enlicitide, which recently completed phase 3 trials, and Lp(a) drugs. - What the future holds for cholesterol drugs Timestamps: 0:00:00 Introduction 13:35 The decline in heart disease mortality 31:02 Surprising cholesterol trivia 55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol 1:22:15 How cholesterol works 1:30:40 The discovery of statins 1:48:44 Should everyone be on statins? 1:57:10 PCSK9 drugs and beyond 2:22:56 Summary: how we got here and the future of cholesterol drugs Watch, listen, or read wherever you get your podcasts. Spotify: Apple: YouTube: Transcript:

New episode of HARD DRUGS! Should everyone be taking statins? Statins have revolutionised heart disease and they're one of many reasons for the long-term decline in cardiovascular mortality. Clinical trials suggest that the more you reduce LDL cholesterol levels, the more you reduce the risks of heart attacks and strokes, with no signal of harms even at the lowest levels. So scientists recommend the earlier they're taken the better, and the lower LDL levels you reach the better. Statins do have some rare side effects – such as muscle weakness and muscle loss in rare cases – but meta-analyses of RCTs find that most other side effects listed on statins' labels do not actually have higher risks than placebo. In this episode, Jacob Trefethen and I chat about all this and much more! - Why it took almost a century for scientists to come to consensus on "the lipid hypothesis": that higher levels of plasma LDL cholesterol causes higher risks of heart disease and that reducing it saves lives. - Drugs that effectively reduce cholesterol levels beyond the effect of statins, such as PCSK9 inhibitors, most of which are monoclonal antibodies, as well as newer siRNA drugs and the macrocyclic peptide enlicitide, which recently completed phase 3 trials, and Lp(a) drugs. - What the future holds for cholesterol drugs Timestamps: 0:00:00 Introduction 13:35 The decline in heart disease mortality 31:02 Surprising cholesterol trivia 55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol 1:22:15 How cholesterol works 1:30:40 The discovery of statins 1:48:44 Should everyone be on statins? 1:57:10 PCSK9 drugs and beyond 2:22:56 Summary: how we got here and the future of cholesterol drugs Watch, listen, or read wherever you get your podcasts. Spotify: Apple: YouTube: Transcript:

Saloni

734,864 Aufrufe • vor 5 Monaten

Retatrutide and reversing insulin resistance and diabetes It’s all right here ⬇️⬇️ It’s all on this video (no you don’t even need to get the research playbook if you don’t want to, but you should) Labs and playbook will be in my stories this evening as well You can’t fix insulin resistance (diabetes) without fixing systemic inflammation They’re not separate problems Inflammation is the root Insulin resistance is the manifestation I’m tired of the Instaexperts and their “magic cures” based on never seeing a patient I’m at over 1 million+ verifiable patients I’m right… I’m ALWAYS right Do you know why? I only speak on what I know and I actually care Run this 90 days and I mean actually do it and HbA1c fasting insulin HOMA-IR etc… All normalize liver fat disappears and biology reverses insulin resistance and diabetes You’re welcome Share this with everyone! Repost this everywhere! Help people! Never Miss Dr Trevor Bachmeyer The Spartan

Retatrutide and reversing insulin resistance and diabetes It’s all right here ⬇️⬇️ It’s all on this video (no you don’t even need to get the research playbook if you don’t want to, but you should) Labs and playbook will be in my stories this evening as well You can’t fix insulin resistance (diabetes) without fixing systemic inflammation They’re not separate problems Inflammation is the root Insulin resistance is the manifestation I’m tired of the Instaexperts and their “magic cures” based on never seeing a patient I’m at over 1 million+ verifiable patients I’m right… I’m ALWAYS right Do you know why? I only speak on what I know and I actually care Run this 90 days and I mean actually do it and HbA1c fasting insulin HOMA-IR etc… All normalize liver fat disappears and biology reverses insulin resistance and diabetes You’re welcome Share this with everyone! Repost this everywhere! Help people! Never Miss Dr Trevor Bachmeyer The Spartan

Dr Trevor Bachmeyer

13,015 Aufrufe • vor 1 Monat

Dr. Aseem Malhotra tells Joe Rogan that a reanalysis of Pfizer and Moderna's original clinical trial data shows that their COVID mRNA vaccines *INCREASE* your risks of serious adverse events, hospitalization, and death: "In my whole career, looking at all of the drugs and knowing about many different prescribed medications, I've never seen something that when you look at the data has such poor effectiveness and unprecedented harms. In the summer of last year, in the journal Vaccine, the highest-impact medical journal for vaccines, they published a reanalysis of Pfizer and Moderna's original double-blinded randomized controlled trial. This is the highest quality of scientific evidence. Joseph Fraiman is an ER doctor and clinical data scientist from Louisiana. Associate editor of the BMJ, Dr. Peter Doshi. Dr. Robert Kaplan from Stanford. Some real eminence of integrity published this reanalysis, and what they found was this. In the trials that led to the approval of regulators worldwide, you were more likely to suffer a severe adverse event from taking the vaccine, hospitalization, disability, or life-changing event than you were to be hospitalized with COVID. This mRNA vaccine should likely have never been approved for a single human in the first place, and that rate of serious adverse events is at least 1 in 800... 1 in 800 is a very, very high figure. We've pulled other vaccines for much less. The 1976 Swine Flu vaccine was pulled because it was found to cause a debilitating neurological condition called Guillan-Barre syndrome in about 1 in 100,000 people. The Rotavirus vaccine was suspended in 1999 because it was found to cause a form of bowel obstruction in kids in 1 of 10,000. This is at least 1 in 800. It's a no-brainer. So the question is, why have we not paused it?" Study: Dr Aseem Malhotra Joe Rogan

Dr. Aseem Malhotra tells Joe Rogan that a reanalysis of Pfizer and Moderna's original clinical trial data shows that their COVID mRNA vaccines INCREASE your risks of serious adverse events, hospitalization, and death: "In my whole career, looking at all of the drugs and knowing about many different prescribed medications, I've never seen something that when you look at the data has such poor effectiveness and unprecedented harms. In the summer of last year, in the journal Vaccine, the highest-impact medical journal for vaccines, they published a reanalysis of Pfizer and Moderna's original double-blinded randomized controlled trial. This is the highest quality of scientific evidence. Joseph Fraiman is an ER doctor and clinical data scientist from Louisiana. Associate editor of the BMJ, Dr. Peter Doshi. Dr. Robert Kaplan from Stanford. Some real eminence of integrity published this reanalysis, and what they found was this. In the trials that led to the approval of regulators worldwide, you were more likely to suffer a severe adverse event from taking the vaccine, hospitalization, disability, or life-changing event than you were to be hospitalized with COVID. This mRNA vaccine should likely have never been approved for a single human in the first place, and that rate of serious adverse events is at least 1 in 800... 1 in 800 is a very, very high figure. We've pulled other vaccines for much less. The 1976 Swine Flu vaccine was pulled because it was found to cause a debilitating neurological condition called Guillan-Barre syndrome in about 1 in 100,000 people. The Rotavirus vaccine was suspended in 1999 because it was found to cause a form of bowel obstruction in kids in 1 of 10,000. This is at least 1 in 800. It's a no-brainer. So the question is, why have we not paused it?" Study: Dr Aseem Malhotra Joe Rogan

KanekoaTheGreat

2,292,761 Aufrufe • vor 3 Jahren

WHY YOU SHOULD BUY $HIMS BEFORE EARNINGS. In this video, we talk about: 1.) Why the stock is crashing 2.) Why everything on the Technicals/ Fundamentals point to a STRONG BUY. 3.) My earnings prediction & fair value Thanks for watching! I know it was a longer video but I always want to be thorough. Comment below if you like this type of content or if your not a fan of videos and rather have posts. YouTube: RonnieV NFA #BuyingOpportunity #BuyTheDip

WHY YOU SHOULD BUY $HIMS BEFORE EARNINGS. In this video, we talk about: 1.) Why the stock is crashing 2.) Why everything on the Technicals/ Fundamentals point to a STRONG BUY. 3.) My earnings prediction & fair value Thanks for watching! I know it was a longer video but I always want to be thorough. Comment below if you like this type of content or if your not a fan of videos and rather have posts. YouTube: RonnieV NFA #BuyingOpportunity #BuyTheDip

RonnieV

66,589 Aufrufe • vor 1 Jahr

Dr. Aseem Malhotra exposes statins: A 1% benefit with hidden costs—time for informed consent Dr. Aseem Malhotra, a renowned cardiologist, has raised critical concerns about statins, one of the most prescribed drugs globally, with 30 million users in the U.S. and up to a billion worldwide. In a recent discussion, he unpacked the shocking truth about their efficacy, urging patients to question the widespread use of these cholesterol-lowering medications. Drawing from industry-sponsored trial data, Dr. Malhotra highlights that for most people—those not at high risk of heart attack—taking a statin daily for five years offers just a 1% chance of preventing a non-fatal heart attack or non-disabling stroke. Critically, this comes with no evidence of prolonging life by even a single day. He emphasizes that this information, available at is rarely communicated to patients due to systemic gaps in medical training, where doctors are not taught to interpret and convey such data effectively. Dr. Malhotra advocates for informed consent, presenting patients with these facts without coercion. Many, he notes, are dismayed by the minimal benefit when weighed against potential side effects, which affect 20-50% of users. These include muscle pain, fatigue, brain fog, erectile dysfunction, joint pain, and stomach issues. Strikingly, he has witnessed elderly patients misdiagnosed with dementia or frailty regain memory and vitality weeks after discontinuing statins. This is not a call to stop medication abruptly, but a plea for patients to engage in informed discussions with their doctors. Dr. Malhotra’s book, A Statin-Free Life, available on Amazon, delves deeper into these findings, offering a comprehensive resource for those seeking clarity on cholesterol management and drug benefits. For evidence-based insights on statins and other medications, visit Dr. Malhotra’s mission is clear: empower patients with knowledge to make health decisions that align with their values and quality of life.

Dr. Aseem Malhotra exposes statins: A 1% benefit with hidden costs—time for informed consent Dr. Aseem Malhotra, a renowned cardiologist, has raised critical concerns about statins, one of the most prescribed drugs globally, with 30 million users in the U.S. and up to a billion worldwide. In a recent discussion, he unpacked the shocking truth about their efficacy, urging patients to question the widespread use of these cholesterol-lowering medications. Drawing from industry-sponsored trial data, Dr. Malhotra highlights that for most people—those not at high risk of heart attack—taking a statin daily for five years offers just a 1% chance of preventing a non-fatal heart attack or non-disabling stroke. Critically, this comes with no evidence of prolonging life by even a single day. He emphasizes that this information, available at is rarely communicated to patients due to systemic gaps in medical training, where doctors are not taught to interpret and convey such data effectively. Dr. Malhotra advocates for informed consent, presenting patients with these facts without coercion. Many, he notes, are dismayed by the minimal benefit when weighed against potential side effects, which affect 20-50% of users. These include muscle pain, fatigue, brain fog, erectile dysfunction, joint pain, and stomach issues. Strikingly, he has witnessed elderly patients misdiagnosed with dementia or frailty regain memory and vitality weeks after discontinuing statins. This is not a call to stop medication abruptly, but a plea for patients to engage in informed discussions with their doctors. Dr. Malhotra’s book, A Statin-Free Life, available on Amazon, delves deeper into these findings, offering a comprehensive resource for those seeking clarity on cholesterol management and drug benefits. For evidence-based insights on statins and other medications, visit Dr. Malhotra’s mission is clear: empower patients with knowledge to make health decisions that align with their values and quality of life.

Camus

107,694 Aufrufe • vor 1 Jahr

UK’s Doctor Crisis: Not a Shortage of Doctors, But a Shortage of Jobs | Dr. Rahmeh Aladwan Think the UK has a doctor shortage? Think again. In this eye-opening breakdown,Dr Rahmeh Aladwan exposes the real crisis facing British medical graduates today—thousands of qualified doctors stuck in career limbo, not because they aren’t skilled, but because there simply aren’t enough training jobs. 🔍 What you’ll learn in this video: Why over 30,000 qualified doctors applied for just 10,000 specialty training spots How competition ratios have skyrocketed (e.g., 73 applicants per cardiothoracic surgery spot) Why the government added only 90 posts to handle a 30,000-applicant surge The truth about locum jobs drying up and being filled by international graduates Why many UK-trained doctors are now leaving for Canada, the US, or Australia The emotional and financial toll: £50k–£60k debt with no guaranteed training pathway This isn’t about tuition fees or a lack of people wanting to study medicine. It’s about a system that trains doctors, then abandons them. 📢 If you’re a medical student, junior doctor, or considering medicine in the UK—this is a must-watch. 👉 Share this video to raise awareness. 💬 Comment below: Have you or someone you know been affected by this training bottleneck? #DoctorCrisis #NHS

UK’s Doctor Crisis: Not a Shortage of Doctors, But a Shortage of Jobs | Dr. Rahmeh Aladwan Think the UK has a doctor shortage? Think again. In this eye-opening breakdown,Dr Rahmeh Aladwan exposes the real crisis facing British medical graduates today—thousands of qualified doctors stuck in career limbo, not because they aren’t skilled, but because there simply aren’t enough training jobs. 🔍 What you’ll learn in this video: Why over 30,000 qualified doctors applied for just 10,000 specialty training spots How competition ratios have skyrocketed (e.g., 73 applicants per cardiothoracic surgery spot) Why the government added only 90 posts to handle a 30,000-applicant surge The truth about locum jobs drying up and being filled by international graduates Why many UK-trained doctors are now leaving for Canada, the US, or Australia The emotional and financial toll: £50k–£60k debt with no guaranteed training pathway This isn’t about tuition fees or a lack of people wanting to study medicine. It’s about a system that trains doctors, then abandons them. 📢 If you’re a medical student, junior doctor, or considering medicine in the UK—this is a must-watch. 👉 Share this video to raise awareness. 💬 Comment below: Have you or someone you know been affected by this training bottleneck? #DoctorCrisis #NHS

Workers Party of Britain

17,609 Aufrufe • vor 2 Monaten

I’ve got something BIG to share… I’m writing a book. Actually, I’ve been writing it for over a year and I’m too excited not to share. It’s called “Who Do You Think You Aren’t”, and it’s not just for women. It’s for anyone who’s ever felt too broken, too loud, too much, or not enough. Man, woman, human… this is for you. This book is about unlearning the shame we were handed, reclaiming our voice, and stepping into the life we were always meant for. If you want a taste of what this book is about, go listen to episode 39 of The Naughty Gym Show, it’s the full recording of my keynote speech from January, and it’s the heart of everything this book will dive into. 🖤 This story has been in me for years, and now I’m finally letting her speak. You can watch it on our YouTube channel or listen where ever you listen to podcasts! #whodoyouthinkyouarent #impostersyndrome #shame #shameless #thenaughtygymshow #unapologeticaf

I’ve got something BIG to share… I’m writing a book. Actually, I’ve been writing it for over a year and I’m too excited not to share. It’s called “Who Do You Think You Aren’t”, and it’s not just for women. It’s for anyone who’s ever felt too broken, too loud, too much, or not enough. Man, woman, human… this is for you. This book is about unlearning the shame we were handed, reclaiming our voice, and stepping into the life we were always meant for. If you want a taste of what this book is about, go listen to episode 39 of The Naughty Gym Show, it’s the full recording of my keynote speech from January, and it’s the heart of everything this book will dive into. 🖤 This story has been in me for years, and now I’m finally letting her speak. You can watch it on our YouTube channel or listen where ever you listen to podcasts! #whodoyouthinkyouarent #impostersyndrome #shame #shameless #thenaughtygymshow #unapologeticaf

Naughty Gym

22,737 Aufrufe • vor 1 Jahr

I’m typically skeptical about Nigerian regulators, but on this one, they may be up to something. Millions of Nigerians are borrowing and repaying airtime loans and have no formal credit history because the telcos are refusing to share that data with the credit bureau. That calls to question what these big telcos are doing with that data and more importantly, the missed opportunities in terms of the quality of policy formulation and product design from financial institutions that could have been achieved if such data was available. Another important point is that why is it too hard for these telcos, especially MTN and Airtel, to partner with at least one local fintech?

I’m typically skeptical about Nigerian regulators, but on this one, they may be up to something. Millions of Nigerians are borrowing and repaying airtime loans and have no formal credit history because the telcos are refusing to share that data with the credit bureau. That calls to question what these big telcos are doing with that data and more importantly, the missed opportunities in terms of the quality of policy formulation and product design from financial institutions that could have been achieved if such data was available. Another important point is that why is it too hard for these telcos, especially MTN and Airtel, to partner with at least one local fintech?

Sir Dickson

38,617 Aufrufe • vor 9 Monaten

Megyn, why don't you come directly me, since it was my post exposing your best friend Tucker? Afraid? Rather than cheap shots & feigned outrage, why not engage me? You're outraged by "what's being done to Candace." But what about what's being done to Jews? How many of your non-Jewish friends have to walk past armed security guards to drop their kids off at PRESCHOOL? Why do you think that is? And do you really think Tucker's rants blaming "Chabad" for war with Iran won't make an awful situation even worse? Is that why you spent more time today flexing about your foreign bot-enhanced "audience" figures than expressing concern about Tucker putting a target on Jews around the world? Or is it because you're still too worried about protecting Candace and Tucker from "Israel-firsters"? But let me assure you of something: The rhetoric you condone or even support from Candace and Tucker is not a game. Nor is it the kind of thing a decent person would ignore in order to boast about clicks and revenue. Maybe you don't care that my children — my oldest is 5 years old — now face even more risk just walking inside any Jewish building or event. But I do. And maybe you don't care that it's the reality for every Jewish family in America. You claim to be "America First," so shouldn't ensuring the safety and security of Americans who happen to be Jewish qualify as "America First"? Or do you still care more about protecting the feelings of Candace and Tucker? You keep claiming you're not anti-Semitic and that you love your "Jewish friends." Then why not prove it? Or at least have the guts to debate me or even just have a real, frank conversation? If not, then please have the decency to stop pretending that you're tough — or that you actually care about the safety of Jews more than your own ego.

Megyn, why don't you come directly me, since it was my post exposing your best friend Tucker? Afraid? Rather than cheap shots & feigned outrage, why not engage me? You're outraged by "what's being done to Candace." But what about what's being done to Jews? How many of your non-Jewish friends have to walk past armed security guards to drop their kids off at PRESCHOOL? Why do you think that is? And do you really think Tucker's rants blaming "Chabad" for war with Iran won't make an awful situation even worse? Is that why you spent more time today flexing about your foreign bot-enhanced "audience" figures than expressing concern about Tucker putting a target on Jews around the world? Or is it because you're still too worried about protecting Candace and Tucker from "Israel-firsters"? But let me assure you of something: The rhetoric you condone or even support from Candace and Tucker is not a game. Nor is it the kind of thing a decent person would ignore in order to boast about clicks and revenue. Maybe you don't care that my children — my oldest is 5 years old — now face even more risk just walking inside any Jewish building or event. But I do. And maybe you don't care that it's the reality for every Jewish family in America. You claim to be "America First," so shouldn't ensuring the safety and security of Americans who happen to be Jewish qualify as "America First"? Or do you still care more about protecting the feelings of Candace and Tucker? You keep claiming you're not anti-Semitic and that you love your "Jewish friends." Then why not prove it? Or at least have the guts to debate me or even just have a real, frank conversation? If not, then please have the decency to stop pretending that you're tough — or that you actually care about the safety of Jews more than your own ego.

Joel Mowbray

225,045 Aufrufe • vor 5 Monaten

Ever wondered why the very meds prescribed to protect your heart might be quietly fogging your mind? Natural health expert Barbara O'Neill pulls back the curtain on statins—the blockbuster cholesterol-lowering drugs—and their surprising ripple effects on the body and brain. In a eye-opening talk, O'Neill explains how statins work by blocking a key pathway in the liver that produces cholesterol. Sounds smart for heart health, right? But here's the twist: Your brain relies on cholesterol to function at its best—it's essential for building cell membranes, producing hormones, and keeping neurons firing. Disrupt that supply, and trouble brews. O'Neill points to a cascade of potential side effects, including memory fog, heightened risks for Alzheimer's and dementia, muscle weakness (hello, rhabdomyolysis vibes), and even links to breast cancer concerns. And get this: If you've been on statins for a decade or more, O'Neill shares a bold nugget of hope—you might be able to taper off under guidance, with one "side effect" being... sharper recall. But she doesn't sugarcoat it: That same liver pathway? It also cranks out CoQ10, the powerhouse antioxidant that shields your heart from oxidative stress. Statins can deplete it, potentially raising your risk of the very heart issues they're meant to prevent. Talk about a plot twist! O'Neill's message? Knowledge is power—empower yourself with the facts before popping another pill. (Pro tip: Always chat with your doc before any changes; this isn't medical advice, just food for thought.)

Ever wondered why the very meds prescribed to protect your heart might be quietly fogging your mind? Natural health expert Barbara O'Neill pulls back the curtain on statins—the blockbuster cholesterol-lowering drugs—and their surprising ripple effects on the body and brain. In a eye-opening talk, O'Neill explains how statins work by blocking a key pathway in the liver that produces cholesterol. Sounds smart for heart health, right? But here's the twist: Your brain relies on cholesterol to function at its best—it's essential for building cell membranes, producing hormones, and keeping neurons firing. Disrupt that supply, and trouble brews. O'Neill points to a cascade of potential side effects, including memory fog, heightened risks for Alzheimer's and dementia, muscle weakness (hello, rhabdomyolysis vibes), and even links to breast cancer concerns. And get this: If you've been on statins for a decade or more, O'Neill shares a bold nugget of hope—you might be able to taper off under guidance, with one "side effect" being... sharper recall. But she doesn't sugarcoat it: That same liver pathway? It also cranks out CoQ10, the powerhouse antioxidant that shields your heart from oxidative stress. Statins can deplete it, potentially raising your risk of the very heart issues they're meant to prevent. Talk about a plot twist! O'Neill's message? Knowledge is power—empower yourself with the facts before popping another pill. (Pro tip: Always chat with your doc before any changes; this isn't medical advice, just food for thought.)

Camus

16,701 Aufrufe • vor 8 Monaten

Twitch founder Emmett Shear on how to resolve product roadmap disagreements Emmett argues that disagreement on what to build is actually quite rare after everyone has talked to users and looked at the data. Most disagreements in startups arise because people like to come up with product ideas without talking to users first: “You talk to your users first, and then you have ideas about your product. Almost everyone does it in the opposite order” He continues: “If you find yourself thinking: ‘I’m going to go talk to my users to validate my product idea’, you’ve gone horribly off the rails…If you haven’t talked to users and you haven’t looked at data, you don’t get to have an opinion about the product. The person who has actually done the work gets to have the opinion. You can have ideas, but they get to make the call.” In the rare case where both people have really talked to users and looked at the data and still disagree on what to build, it’s best to just have someone who is in charge (e.g. CEO). Don’t avoid conflict—talk and argue about it. But then let the decision maker make the call—otherwise decision making will just be way too slow. Reddit cofounder Steve Huffman adds to this: “I find myself saying one of two things a lot: (1) I don’t want to argue about it if we can just test it, and (2) I’m very willing to be surprised on this.” Video source: Stanford Online (2017)

Twitch founder Emmett Shear on how to resolve product roadmap disagreements Emmett argues that disagreement on what to build is actually quite rare after everyone has talked to users and looked at the data. Most disagreements in startups arise because people like to come up with product ideas without talking to users first: “You talk to your users first, and then you have ideas about your product. Almost everyone does it in the opposite order” He continues: “If you find yourself thinking: ‘I’m going to go talk to my users to validate my product idea’, you’ve gone horribly off the rails…If you haven’t talked to users and you haven’t looked at data, you don’t get to have an opinion about the product. The person who has actually done the work gets to have the opinion. You can have ideas, but they get to make the call.” In the rare case where both people have really talked to users and looked at the data and still disagree on what to build, it’s best to just have someone who is in charge (e.g. CEO). Don’t avoid conflict—talk and argue about it. But then let the decision maker make the call—otherwise decision making will just be way too slow. Reddit cofounder Steve Huffman adds to this: “I find myself saying one of two things a lot: (1) I don’t want to argue about it if we can just test it, and (2) I’m very willing to be surprised on this.” Video source: Stanford Online (2017)

Startup Archive

29,639 Aufrufe • vor 1 Jahr

WHAT IS THE TRUTH Richard Heart? NOBODY WITH A FOLLOWING HAS THE BALLS TO TAG YOU AND ASK THE EXACT QUESTION THEY WANT TO KNOW............. I DO! I THINK THE BIG QUESTION PEOPLE HAVE, NOT ME, I COULD CARE LESS, BUT OTHERS WANT TO KNOW, THOSE PEOPLE THAT YOU HAD CONVERSATIONS WITH...... ARE THEY BEING BAD ACTORS ON #PULSECHAIN? IF YOU CAN NOT ANSWER WHY OR WHY NOT, I UNDERSTAND WHY........ THEY DON'T. LIKE AND RETWEET IF YOU ARE NOT A COWARD AND WANT THE ANSWER TO THIS ABOUT $PDAI IF YOU WANT TO ASK YOUR QUESTION, FEEL FREE IN THE COMMENTS. EITHER WAY, I'M GOOD

WHAT IS THE TRUTH Richard Heart? NOBODY WITH A FOLLOWING HAS THE BALLS TO TAG YOU AND ASK THE EXACT QUESTION THEY WANT TO KNOW............. I DO! I THINK THE BIG QUESTION PEOPLE HAVE, NOT ME, I COULD CARE LESS, BUT OTHERS WANT TO KNOW, THOSE PEOPLE THAT YOU HAD CONVERSATIONS WITH...... ARE THEY BEING BAD ACTORS ON #PULSECHAIN? IF YOU CAN NOT ANSWER WHY OR WHY NOT, I UNDERSTAND WHY........ THEY DON'T. LIKE AND RETWEET IF YOU ARE NOT A COWARD AND WANT THE ANSWER TO THIS ABOUT $PDAI IF YOU WANT TO ASK YOUR QUESTION, FEEL FREE IN THE COMMENTS. EITHER WAY, I'M GOOD

MOON KING B-ROOTS

25,821 Aufrufe • vor 1 Jahr

This is—without a doubt—the longest I’ve ever sat on a video before releasing it. Because once I open this Pandora’s box, there’s no closing it. 🚨Full Video: In this video, I share my personal decision to walk around with an LDL of 574 mg/dl and a total cholesterol over 700. But this isn’t about one biomarker, or one study. Decisions about whether to act, when to act, and how to act aren’t simple math problems. Individual complexity and thoughtful consideration can turn what looks like a straightforward equation into something far more nuanced. 🚨This video isn’t about telling you what to think—it’s about showing you how I think. It’s not about dogma or conspiracy. It’s about authenticity, transparency, and the kind of nuanced conversations we need to have if we’re going to approach this topic responsibly. And I say that without irony. If you watch all the way through—rather than jumping to conclusions—you might be surprised by where I land… and what I’m planning next. We don't need to agree. We do need to be willing to keep our eyes, ears, and hearts open to new data and divergent opinions. cc Dave Feldman Adrian Soto-Mota Bret Scher, MD Dr Aseem Malhotra Jan Ellison Baszucki Metabolic Mind Coalition for Metabolic Health Austin Dudzinski, PharmD, BCACP Eric Rodgers Andrew Koutnik, Ph.D. Peter Attia (I'm sure we'll have a productive and cordial chat one day)

This is—without a doubt—the longest I’ve ever sat on a video before releasing it. Because once I open this Pandora’s box, there’s no closing it. 🚨Full Video: In this video, I share my personal decision to walk around with an LDL of 574 mg/dl and a total cholesterol over 700. But this isn’t about one biomarker, or one study. Decisions about whether to act, when to act, and how to act aren’t simple math problems. Individual complexity and thoughtful consideration can turn what looks like a straightforward equation into something far more nuanced. 🚨This video isn’t about telling you what to think—it’s about showing you how I think. It’s not about dogma or conspiracy. It’s about authenticity, transparency, and the kind of nuanced conversations we need to have if we’re going to approach this topic responsibly. And I say that without irony. If you watch all the way through—rather than jumping to conclusions—you might be surprised by where I land… and what I’m planning next. We don't need to agree. We do need to be willing to keep our eyes, ears, and hearts open to new data and divergent opinions. cc Dave Feldman Adrian Soto-Mota Bret Scher, MD Dr Aseem Malhotra Jan Ellison Baszucki Metabolic Mind Coalition for Metabolic Health Austin Dudzinski, PharmD, BCACP Eric Rodgers Andrew Koutnik, Ph.D. Peter Attia (I'm sure we'll have a productive and cordial chat one day)

Nick Norwitz MD PhD

138,564 Aufrufe • vor 10 Monaten

this is so sweet 👤 when i listen to seventeen’s music, i know that there’s almost no songs about breaking up or that kind of vibe. even if it’s a song about love, it’s like “i’m cheering on for your love” or “i’m cheering on for your youth” and if there’s a subject to the love, it’s “you’re really pretty” or “what can i do to adore you even more?” there are many of your songs expressed in this way and that kind of direction is so cool and admirable. i hope that you continue to be artists who can shine a beautiful light on many people and let us hear those kinds of songs often 🍑 thank you. i’m so touched seriously

this is so sweet 👤 when i listen to seventeen’s music, i know that there’s almost no songs about breaking up or that kind of vibe. even if it’s a song about love, it’s like “i’m cheering on for your love” or “i’m cheering on for your youth” and if there’s a subject to the love, it’s “you’re really pretty” or “what can i do to adore you even more?” there are many of your songs expressed in this way and that kind of direction is so cool and admirable. i hope that you continue to be artists who can shine a beautiful light on many people and let us hear those kinds of songs often 🍑 thank you. i’m so touched seriously

🌌

1,110,933 Aufrufe • vor 1 Jahr

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 Aufrufe • vor 1 Jahr

iShowSpeed explains why Ronaldo is the GOAT IShowSpeed: "What about you? Ronaldo or Messi?" Shannon: "Messi." IShowSpeed: "All right, peace out." IShowSpeed: "Messi? Really? Yeah, yeah, yeah. Yeah. Why? Yeah. Yeah. Yeah. Why? He can just… You don’t know nothing about football." Shannon: "I don’t know as I’m as versed in it as you know, but from what I’ve seen and…" IShowSpeed: "From what you’ve seen. What did you see?" Shannon: "From what I’ve seen. I saw him in the World Cup. See, look. That’s it. Look. You being too simple-minded. " "What about all those balls? Does it count for anything? A ball in the yard? Yeah. Yes. Who has the most?" IShowSpeed: "Ronaldo does." Shannon: "Messi does. But not Strato. You don’t understand. You don’t understand. Okay, well help me understand." IShowSpeed: "See, I don’t wanna get too deep into this." Shannon Sharpe: "Get deep." IShowSpeed: "I don’t wanna get… okay, listen, listen, listen. Ronaldo should have at least nine Ballon d’Ors."

iShowSpeed explains why Ronaldo is the GOAT IShowSpeed: "What about you? Ronaldo or Messi?" Shannon: "Messi." IShowSpeed: "All right, peace out." IShowSpeed: "Messi? Really? Yeah, yeah, yeah. Yeah. Why? Yeah. Yeah. Yeah. Why? He can just… You don’t know nothing about football." Shannon: "I don’t know as I’m as versed in it as you know, but from what I’ve seen and…" IShowSpeed: "From what you’ve seen. What did you see?" Shannon: "From what I’ve seen. I saw him in the World Cup. See, look. That’s it. Look. You being too simple-minded. " "What about all those balls? Does it count for anything? A ball in the yard? Yeah. Yes. Who has the most?" IShowSpeed: "Ronaldo does." Shannon: "Messi does. But not Strato. You don’t understand. You don’t understand. Okay, well help me understand." IShowSpeed: "See, I don’t wanna get too deep into this." Shannon Sharpe: "Get deep." IShowSpeed: "I don’t wanna get… okay, listen, listen, listen. Ronaldo should have at least nine Ballon d’Ors."

Mati

174,982 Aufrufe • vor 1 Monat